

HTG Molecular Diagnostics Hires Novartis Veteran as VP Translational Science and Chief Medical Officer

September 13, 2012 10:08 AM ET

TUCSON, Ariz. (September 13, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Vijay Modur, M.D., Ph.D. as vice president of translational science and chief medical officer. Dr. Modur joins HTG Molecular Diagnostics from Novartis Molecular Diagnostics where he served as global head of diagnostic discovery. Prior positions with Novartis Oncology included that of senior director, Cambridge site head of oncology biomarkers and clinical imaging and director/clinical research physician. Dr. Modur also contributed to Merck Research Laboratories as an associate director. Dr. Modur earned an M.D. at Karnatak University, a Ph.D. in Experimental Pathology at the University of Utah School of Medicine, and completed his residency at the Washington University School of Medicine.

TJ Johnson, CEO of HTG Molecular Diagnostics states, “Dr. Modur’s practical experience combined with his medical, science, and business acumen will be an invaluable addition to the HTG Molecular Diagnostics leadership team. He is a very well respected, thoughtful, seasoned and credible individual who we are thrilled to have championing the medical utility of our test menu.” Dr. Modur will work with the HTG Molecular companion diagnostics team as a scientific and medical liaison and will functionally lead research teams to use qNPA for integrated oncology diagnostic solutions based on targeted mutations, gene fusions and gene expression.